NASDAQ:AKBA - Akebia Therapeutics, Inc.
$6.71
 $-0.21
-3.03%
4:00PM EDT
2019-04-18
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD). Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  AKBA     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 86   203. 85   241. 91  
42 stocks rank:  3. 45 K 1. 44 K 1. 05 K
# analyst opinions:  10. 00   14. 51   13. 97  
mean recommendation:  2. 10   2. 09   2. 01  

quick ratio:  1. 27   5. 27   1. 81  
current ratio:  1. 76   5. 62   2. 25  

target price low:  9. 00   84. 80   115. 21  
target price avg:  18. 30   111. 51   137. 51  
target price high:  9. 55   135. 81   157. 84  
1-yr high:  11. 34   114. 23   138. 78  
last close:  6. 71   87. 66   116. 69  
50-day avg:  7. 42   95. 54   123. 44  
200-day avg:  7. 84   94. 25   121. 11  
1-yr low:  5. 39   72. 78   98. 34  
volume:  1. 56 M 4. 11 M 8. 07 M
50-day avg volume:  1. 33 M 2. 76 M 5. 02 M
200-day avg volume:  877. 20 K 2. 92 M 4. 59 M

1-day return:  -3. 03 % -0. 41 % 0. 07 %
this week return:  -6. 93 % -5. 74 % -4. 11 %
12-wk return:  13. 92 % 1. 61 % -0. 05 %
52-wk return:  -25. 11 % 3. 12 % 8. 78 %

enterprise value (EV):  -183. 85 M 48. 94 B 114. 64 B
market cap:  785. 89 M 43. 07 B 104. 73 B
EBITDA:  -147. 87 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  1. 24   4. 22   12. 73  
enterprise/revenue (EV/R):  -0. 89   63. 17   12. 84  
total revenue:  207. 74 M 10. 62 B 38. 47 B
total debt:  15. 00 M 12. 24 B 16. 73 B
debt/equity:  2. 36   46. 71   89. 62  
net income (common):  -143. 59 M 2. 20 B 4. 20 B

shares outstanding:  117. 12 M 571. 70 M 1. 24 B
shares:  14. 05 M 571. 81 M 1. 23 B
shares short:  7. 04 M 10. 17 M 13. 00 M
shares short prior month:  6. 97 M 9. 54 M 17. 33 M
short ratio:  4. 56   5. 41   3. 28  
short % of float:  13. 16 % 5. 45 % 2. 38 %
total cash/share:  17. 58   11. 14   9. 33  
total cash:  321. 64 M 6. 71 B 7. 15 B
free cash flow:  -70. 56 M 3. 58 B 2. 96 B
operating cash flow:  -97. 49 M 4. 15 B 4. 30 B

book value:  5. 44   12. 78   26. 92  
price/book:  1. 23   3. 06   -1. 74  
gross profits:  -84. 84 M 8. 04 B 34. 86 B
operating margins:  -72. 34 % -725. 35 % -89. 04 %
EBITDA margins:  -71. 18 % 10. 94 % 22. 51 %
profit margins:  -69. 12 % 7. 81 % 10. 57 %
gross margins:  -40. 83 % 37. 08 % 55. 70 %

1-yr max volatility:  -15. 43 % --- ---
1-yr mean volatility:  -0. 05 % 0. 03 % 0. 04 %

1-yr EPS:  -2. 47   2. 40   4. 10  
forward EPS:  -0. 62   3. 97   7. 13  
P/E:  -2. 71   13. 63   22. 72  
forward P/E:  -10. 82   -15. 95   13. 99  
PE/G:  0. 08   -1. 65   -1. 32  
growth:  -33. 90 % 127. 12 % 29. 61 %
earnings high:  -0. 25   1. 00   1. 66  
earnings avg:  -0. 39   0. 77   1. 53  
earnings low:  -0. 52   0. 50   1. 39  
revenue high:  90. 26 M 2. 68 B 10. 78 B
revenue avg:  78. 35 M 2. 59 B 10. 57 B
revenue low:  71. 63 M 2. 49 B 10. 36 B
return on assets:  -13. 80 % -2. 75 % 4. 55 %
return on equity:  -37. 86 % -18. 45 % 5. 46 %
revenue growth:  -33. 90 % 92. 86 % 18. 96 %
revenue/share:  3. 58   13. 29   55. 46  

beta (1yr vs S&P500):  1. 80   1. 25   0. 93  
sharpe (1yr):  -0. 22   0. 37   0. 70  

held % insiders:  8. 23 % 6. 39 % 3. 38 %
held % institutions:  70. 12 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : AKBA
.    + 0.116 =         0.116 :: INITIAL WEIGHT
.   + 45.126 =        45.243 :: spline projection addition
.    x 1.431 =        64.762 :: industry recommendation factor
.    x 2.067 =       133.834 :: symbol recommendation factor
.    x 0.999 =       133.649 :: return on assets factor
.    x 0.996 =       133.143 :: return on equity factor
.    x 0.997 =       132.691 :: revenue growth factor
.    x 2.313 =       306.953 :: current ratio factor
.    x 1.707 =       523.974 :: quick ratio factor
.    x 1.104 =       578.581 :: short ratio factor
.    x 2.012 =      1164.298 :: price-to-book factor
.    x 1.025 =      1193.333 :: debt-to-equity factor
.    x 1.138 =      1357.853 :: EBITDA multiple vs industry factor
.    x 5.467 =      7423.532 :: EBITDA multiple factor
.     x 2.13 =     15813.165 :: P/E weight
.     x 1.88 =     29732.951 :: PE/G factor
.    x 1.464 =     43532.613 :: beta factor
.    x 0.216 =      9403.587 :: sharpe factor
.    x 1.616 =     15193.223 :: target low factor
.    x 1.438 =     21849.158 :: target mean factor
.    x 1.065 =     23270.436 :: target high factor
.     x 1.31 =     30481.662 :: industry 2-weeks return factor
.     x 0.92 =     28053.286 :: "drift" penalty 1 days ago
.    x 0.989 =     27746.716 :: overall "drift" factor
.    x 0.999 =     27728.649 :: largest single-day jump factor
.    x 0.096 =      2648.391 :: low price factor
.      x 1.0 =      2647.961 :: factor hist industry gain for week 16
.   cubeRoot =        13.835 :: reduced to standardize
.   - 22.259 =          0.86 :: add/subtract for performance
.                       0.86 :: FINAL WEIGHT for NASDAQ:AKBA


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org